Potential therapeutic targets for Mpox: the evidence to date

天花 天花病毒 公共卫生 爆发 医学 猴痘 疾病 正痘病毒 天花病毒 病毒学 牛痘 生物 接种疫苗 遗传学 护理部 病理 基因 重组DNA
作者
Siddappa N. Byrareddy,Kalicharan Sharma,Shrikesh Sachdev,Athreya S. Reddy,Arpan Acharya,Kaylee M. Klaustermeier,Christian L. Lorson,Kamal Singh
出处
期刊:Expert Opinion on Therapeutic Targets [Taylor & Francis]
卷期号:27 (6): 419-431 被引量:6
标识
DOI:10.1080/14728222.2023.2230361
摘要

ABSTRACTIntroduction The global Mpox (MPX) disease outbreak caused by the Mpox virus (MPXV) in 2022 alarmed the World Health Organization (WHO) and health regulation agencies of individual countries leading to the declaration of MPX as a Public Health Emergency. Owing to the genetic similarities between smallpox-causing poxvirus and MPXV, vaccine JYNNEOS, and anti-smallpox drugs Brincidofovir and Tecovirimat were granted emergency use authorization by the United States Food and Drug Administration. The WHO also included cidofovir, NIOCH-14, and other vaccines as treatment options.Areas covered This article covers the historical development of EUA-granted antivirals, resistance to these antivirals, and the projected impact of signature mutations on the potency of antivirals against currently circulating MPXV. Since a high prevalence of MPXV infections in individuals coinfected with HIV and MPXV, the treatment results among these individuals have been included.Expert opinion All EUA-granted drugs have been approved for smallpox treatment. These antivirals show good potency against Mpox. However, conserved resistance mutation positions in MPXV and related poxviruses, and the signature mutations in the 2022 MPXV can potentially compromise the efficacy of the EUA-granted treatments. Therefore, MPXV-specific medications are required not only for the current but also for possible future outbreaks.KEYWORDS: MpoxCidofovirBrincidofovirBrincidofovirTecovirimatOPG71OPG57F8LC19L Article highlights The 2022 Mpox outbreak and the volume of infections showed that poxviruses remain a constant threat to global health. Signature mutations in currently circulating Mpox viruses (MPXV) may be contributing in unknown ways to the outbreak. Therefore, the role of these mutations in viral replication needs to be established.There are no Mpox-specific treatments available. Limited studies indicate that the treatments that have been granted emergency use authorization (EUA) have good efficacy against MPXV. However, additional, and more robust studies are needed to establish the potency of these drugs against MPXV.Nucleic acid polymerases are the most sought-after antiviral targets. Considering their essential role in virus replication, research to discover poxvirus DNA polymerase inhibitors is needed. Additionally, other components of the viral DNA replication holoenzyme, such as DNA helicase, should be extensively characterized so that new antivirals can be developed against such targets.The current MPXV was most prevalent among a specific group of individuals (men who have sex with men, and bisexuals). Many of these individuals are coinfected with HIV and MPXV. Therefore, drugs targeting MPXV and HIV coinfection need to be developed.Abbreviations BCV=BrincidofovirBPXV=Buffalopox virusCDV=CidofovirCPXV=Cowpox virusC19L -=Mpox phospholipase D-like proteinEUA=Emergency Use AuthorizationEV=enveloped virionF8L=Mpox DNA polymeraseHBV=hepatitis B virusHCV=hepatitis C virusHIV=human papillomavirusHSV1=herpes simplex virusKF=Klenow FragmentMPX=Mpox virusMV=mature virionOPG=Orthopoxvirus genePCNA=Proliferation Cell Nuclear AntigenPHE=Public Health EmergencyTAF=tenofovir alafenamideTDF=tenofovir disoproxilUS-HHS=United States Human Health Services AdministrationVACV=Vaccinia virusVARV=variola virusvRNAP=DNA-dependent RNA polymeraseWHO=World Health OrganizationWV=wrapped virionAcknowledgmentsK. Singh acknowledges the computation facilities of the Molecular Interactions Core at the University of Missouri, Columbia, MO 65212. We also thank numerous laboratories that have enormously contributed to poxvirus research, but we could not cite their work.Declaration of interestCL. Lorson is cofounder and chief scientific officer of Shift Pharmaceuticals. CL. Lorson has received in excess of $10,000 in income per annum from Shift Pharmaceuticals. CL. Lorson and MU share patents on compounds licensed by Shift Pharmaceuticals and planned patents for additional compounds (United States patent nos. 9,885,040; 10,472,630; and 11,136,580). K Singh is chief scientific officer for Sanctum Therapeutics Corporation. K Singh has received in excess of $10,000 in income per annum from Sanctum Therapeutics Corporation. K Singh and MU share patents on compounds licensed by Sanctum Therapeutics Corporation and planned patents for additional compounds (United States patent nos. US16/311,136; PCT/US2020/36658; US 63/262,611; US 63/200,366). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingK Singh was partially funded by the Bond Life Sciences Center (Early Concept grant), a subcontract from Emory University (5R37AI076119), and the University of Missouri startup support.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wangyuyan完成签到 ,获得积分10
刚刚
zzd发布了新的文献求助10
刚刚
丘比特的应助被weiyichen采纳,获得10
1秒前
赵yy的应助被快乐的忆安采纳,获得10
1秒前
1秒前
2秒前
亦风完成签到,获得积分10
2秒前
丘比特的应助被taoan26采纳,获得10
2秒前
3秒前
玄轩小悟风完成签到,获得积分10
3秒前
3秒前
4秒前
小笨蛋发布了新的文献求助10
4秒前
欢喜的忆枫完成签到,获得积分10
5秒前
传奇3的应助被魏同心采纳,获得10
5秒前
匆匆发布了新的文献求助10
6秒前
6秒前
7秒前
7秒前
7秒前
7秒前
7秒前
7秒前
7秒前
孙兆楠发布了新的文献求助30
7秒前
一周困八天的应助被雨落松山采纳,获得20
7秒前
Leona完成签到,获得积分10
7秒前
8秒前
8秒前
蒲公英那般随遇而安完成签到,获得积分20
8秒前
9秒前
冰海战记发布了新的文献求助20
9秒前
9秒前
桐桐的应助被言希采纳,获得10
9秒前
等待听安完成签到 ,获得积分10
10秒前
董梓轩发布了新的文献求助10
10秒前
科烟生完成签到,获得积分10
10秒前
瘦瘦完成签到,获得积分10
10秒前
飘逸的傲霜完成签到,获得积分10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193605
求助须知:如何正确求助?哪些是违规求助? 9579751
关于积分的说明 21867369
捐赠科研通 7793242
什么是DOI,文献DOI怎么找? 3437325
关于科研通互助平台的介绍 2560761
邀请新用户注册赠送积分活动 2484193